Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS

NCT00925002 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00925002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00925002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2009
Completion date
July 8, 2020
Enrollment
93 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

attr-pn